Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bitwise Crypto Industry Innovators ETF (BITQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bitwise Crypto Industry Innovators ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.86 (market cap $29.60B), while Bitwise Crypto Industry Innovators ETF trades at $22.59. The key difference: Bitwise Crypto Industry Innovators ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BITQ | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Crypto-linked |
52-Week High | $491.22 | $30.43 |
52-Week Low | $205.48 | $16.74 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
BITQ trades at $22.77, up 2.59% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks available fundamental data such as P/E, revenue, or earnings metrics. Recent news highlights institutional interest in crypto ETFs, though BITQ itself is a US stock with no direct crypto operations.
The outlook remains cautious due to bearish technicals and absent financials. Risks include market volatility and competition, while opportunities hinge on future earnings clarity. Investors should await fundamental updates for a clearer investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →
